Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Xilio Therapeutics (Nasdaq: XLO), a clinical-stage biotechnology company focused on tumor-activated immuno-oncology therapies, has granted a non-qualified stock option to its new Chief Legal Officer, Caroline Hensley. The option, effective January 1, 2025, allows for the purchase of 375,000 shares of common stock at an exercise price of $0.955 per share, matching the company's closing price on December 31, 2024.
The stock option has a ten-year term with a vesting schedule where 25% of shares vest after the first year of employment, followed by the remaining 75% vesting in 36 monthly installments. This grant was made under Xilio's 2022 Inducement Stock Incentive Plan and complies with Nasdaq Listing Rule 5635(c)(4).
Xilio Therapeutics (Nasdaq: XLO), un'azienda di biotecnologia in fase clinica focalizzata su terapie immuno-oncologiche attivate da tumori, ha concesso un'opzione su azioni non qualificata al suo nuovo Chief Legal Officer, Caroline Hensley. L'opzione, valida dal 1 gennaio 2025, consente l'acquisto di 375.000 azioni ordinarie a un prezzo di esercizio di $0,955 per azione, corrispondente al prezzo di chiusura dell'azienda del 31 dicembre 2024.
L'opzione sulle azioni ha un termine di dieci anni con un piano di maturazione in cui il 25% delle azioni matura dopo il primo anno di impiego, seguito dal 75% rimanente che matura in 36 rate mensili. Questa concessione è stata effettuata nell'ambito del Piano di Incentivi Azionari per Induzione 2022 di Xilio e rispetta la Regola di Quotazione Nasdaq 5635(c)(4).
Xilio Therapeutics (Nasdaq: XLO), una empresa de biotecnología en etapa clínica centrada en terapias de inmuno-oncología activadas por tumores, ha otorgado una opción de acciones no calificadas a su nueva Directora Jurídica, Caroline Hensley. La opción, efectiva a partir del 1 de enero de 2025, permite la compra de 375,000 acciones ordinarias a un precio de ejercicio de $0.955 por acción, coincidiendo con el precio de cierre de la empresa del 31 de diciembre de 2024.
La opción de acciones tiene un plazo de diez años con un calendario de adquisición donde el 25% de las acciones se adquiere después del primer año de empleo, seguido del 75% restante que se adquiere en 36 pagos mensuales. Esta concesión se realizó bajo el Plan de Incentivos de Acciones por Inducción 2022 de Xilio y cumple con la Regla de Cotización Nasdaq 5635(c)(4).
Xilio Therapeutics (Nasdaq: XLO), 종양 활성화 면역 종양학 치료에 집중하는 임상 단계의 생명공학 회사는 새로운 법률 고문인 Caroline Hensley에게 비적격 주식 옵션을 부여했습니다. 이 옵션은 2025년 1월 1일부터 유효하며 375,000주의 보통 주식을 주당 $0.955의 행사 가격으로 구매할 수 있도록 하며, 이는 2024년 12월 31일 회사의 종가와 일치합니다.
주식 옵션은 10년의 기간을 가지며, 최초 1년 근무 후 25%의 주식이 매수권을 부여받고, 나머지 75%는 36개월 분할로 매수권을 부여받습니다. 이 부여는 Xilio의 2022 유도 주식 인센티브 계획에 따라 이루어졌으며 Nasdaq 상장 규칙 5635(c)(4)를 준수합니다.
Xilio Therapeutics (Nasdaq: XLO), une entreprise de biotechnologie en phase clinique axée sur les thérapies d'immuno-oncologie activées par les tumeurs, a accordé une option d'achat d'actions non qualifiée à sa nouvelle Directrice Juridique, Caroline Hensley. Cette option, qui prendra effet le 1er janvier 2025, permet l'achat de 375 000 actions ordinaires à un prix d'exercice de 0,955 $ par action, correspondant au prix de clôture de l'entreprise du 31 décembre 2024.
Cette option d'achat d'actions a une durée de dix ans avec un calendrier d'acquisition où 25 % des actions seront acquises après la première année d'emploi, suivies des 75 % restants qui seront acquis en 36 versements mensuels. Cette attribution a été effectuée dans le cadre du Plan d'Incitation d'Achats d'Actions par Induction 2022 de Xilio et est conforme à la Règle de Cotation Nasdaq 5635(c)(4).
Xilio Therapeutics (Nasdaq: XLO), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das sich auf tumorrelevante Immunonkologietherapien konzentriert, hat seiner neuen Chefsyndikusanwältin, Caroline Hensley, eine nicht qualifizierte Aktienoption gewährt. Die Option, die ab dem 1. Januar 2025 wirksam ist, ermöglicht den Kauf von 375.000 Aktien zum Ausübungspreis von $0,955 pro Aktie, was dem Schlusskurs des Unternehmens am 31. Dezember 2024 entspricht.
Die Aktienoption hat eine Laufzeit von zehn Jahren mit einem Vesting-Plan, bei dem 25 % der Aktien nach dem ersten Beschäftigungsjahr vested, gefolgt von den verbleibenden 75 %, die in 36 monatlichen Raten vested. Diese Gewährung erfolgte gemäß dem Aktienoptionsplan von Xilio für die Induktion 2022 und entspricht der Nasdaq-Listing-Regel 5635(c)(4).
- None.
- None.
WALTHAM, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, effective January 1, 2025, the company granted a non-qualified stock option to purchase 375,000 shares of its common stock to Caroline Hensley, its newly hired Chief Legal Officer, under Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan.
The stock option has an exercise price of
The stock option is subject to the terms and conditions of Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan, as well as the terms and conditions of the stock option agreement covering the grant and were made as an inducement material to the individual entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).
About Xilio Therapeutics
Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines, antibodies, bispecifics and immune cell engagers. Learn more by visiting www.xiliotx.com and follow us on LinkedIn (Xilio Therapeutics, Inc.).
This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.
Investor and Media Contact:
Scott Young
Vice President, Investor Relations and Corporate Communications
investors@xiliotx.com
FAQ
What is the exercise price of XLO's stock options granted to the new CLO in January 2025?
How many shares were included in XLO's stock option grant to Caroline Hensley?
What is the vesting schedule for XLO's January 2025 inducement grant?
How long is the term of XLO's January 2025 inducement stock option grant?
